BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy
PR Newswire
THOUSAND OAKS, Calif., June 19, 2018
PR Newswire
THOUSAND OAKS, Calif., June 19, 2018
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey